Approach to menopausal symptoms in women with breast cancer

被引:22
作者
Stearns V. [1 ]
Hayes D.F. [1 ]
机构
[1] The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, 48109-0942, MI
关键词
Breast Cancer Survivor; Clonidine; Danazol; Main Drug Interaction; Progestin;
D O I
10.1007/s11864-002-0064-6
中图分类号
学科分类号
摘要
Hot flashes represent one of the most bothersome complaints in breast cancer survivors. In the last two decades, studies investigated several agents and natural compounds to treat these symptoms. Hormones such as estrogens and progestins remain the most beneficial treatment. However, many physicians and patients are reluctant to use these therapies because of the controversy regarding the hormonal effects on tumor growth and progression. Unfortunately, most natural and nonconventional remedies that have been scientifically investigated appear disappointing. Selective serotonin re-uptake inhibitors and other agents that seem to work in similar ways have been investigated over the last few years in Phase II and III trials. Mature results from two prospective, randomized, placebo-controlled trials reveal that selective serotonin re-uptake inhibitors are well tolerated, reduce hot flashes by 50%–60%, and improve sleep and libido. Selective serotonin re-uptake inhibitors should be considered as a first-line nonhormonal pharmacologic therapy for women with menopausal symptoms. © 2002, Current Science Inc.
引用
收藏
页码:179 / 190
页数:11
相关论文
共 79 条
[1]  
Kronenberg F., Hot flashes: epidemiology and physiology, Ann N Y Acad Sci, 592, pp. 52-86, (1990)
[2]  
Resident Population Estimates of the United States by Age and Sex, (1999)
[3]  
Kronenberg F., Hot flashes: phenomenology, quality of life, and search for treatment options, Exp Gerontol, 29, pp. 319-336, (1994)
[4]  
Bachmann G.A., Vasomotor flushes in menopausal women, Am J Obstet Gynecol, 180, pp. S312-S316, (1999)
[5]  
Erlik Y., Meldrum D.R., Judd H.L., Estrogen levels in postmenopausal women with hot flashes, Obstet Gynecol, 59, pp. 403-407, (1982)
[6]  
Chiechi L.M., Ferreri R., Granieri M., Et al., Climacteric syndrome and body-weight, Clin Exp Obstet Gynecol, 24, pp. 163-166, (1997)
[7]  
Gold E.B., Sternfeld B., Kelsey J.L., Et al., Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age, Am J Epidemiol, 152, pp. 463-473, (2000)
[8]  
Schwingl P.J., Hulka B.S., Harlow S.D., Risk factors for menopausal hot flashes, Obstet Gynecol, 84, pp. 29-34, (1994)
[9]  
Grisso J.A., Freeman E.W., Maurin E., Et al., Racial differences in menopause information and the experience of hot flashes, J Gen Intern Med, 14, pp. 98-103, (1999)
[10]  
Obermeyer C.M., Menopause across cultures: a review of the evidence, Menopause, 7, pp. 184-192, (2000)